Jun 07, 2022 / 12:00PM GMT
Editor
This transcript is incomplete due to a portion of the audio being unavailable. The following summary is not a verbatim representation of this missing audio portion and has been provided by the Company.
Peter Dannenbaum - Merck & Co., Inc. - VP of IR
[Good morning. I am Peter Dannenbaum, head of investor relations. Welcome to Merck's ASCO investor event. Thank you for joining us today, both those here in the room in Chicago and those on the webcast.
Presenting from Merck today are Dr. Dean Li, President of Merck Research Labs; Dr. Eliav Barr, Head of Global Clinical Development and Chief Medical Officer; Dr. Eric Rubin, Head of Early-Stage Oncology Clinical Development; and Jannie Oosthuizen, President of U.S. Human Health.
Our agenda includes roughly 30 minutes of upfront remarks, followed by 30 minutes of Q&A. Those tuning in virtually can submit questions via the webcast or e-mail me directly at [email protected].
Joining for the Q&A session will be Dr. Scot Ebbinghaus and Dr. Greg Lubinecki from our Oncology
Merck & Co Inc at ASCO Annual Meeting Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers